Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 3/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3075887 | 1.00 | RORC (0.32) | RORCTRPV1RBP4HSD11B1THRB | |
| SCHEMBL3063699 | 0.89 | RBP4 (0.33) | RORCTRPV1RBP4HSD11B1 | |
| SCHEMBL3071056 | 0.89 | RBP4 (0.33) | RORCTRPV1RBP4HSD11B1 | |
| SCHEMBL3075488 | 0.85 | TYRO3 (0.33) | RORCTRPV1RBP4HDAC4 | |
| SCHEMBL3183940 | 0.85 | TYRO3 (0.33) | RORCTRPV1RBP4HDAC4 | |
| SCHEMBL3067818 | 0.85 | TYRO3 (0.33) | RORCTRPV1RBP4HDAC4 | |
| SCHEMBL3074543 | 0.84 | OXTR (0.33) | TRPV1RBP4HSD11B1 | |
| SCHEMBL3058815 | 0.82 | F10 (0.37) | RORCTRPV1RBP4HSD11B1 | |
| SCHEMBL3075890 | 0.79 | IRAK4 (0.38) | RBP4HSD11B1 | |
| SCHEMBL3068198 | 0.76 | TRPV1 (0.32) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | BASKARAN SUBRAMANIAN | 2010-10-28 | — | — | US | claimed |
| WO-2010091411-A1 | PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | claimed |
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | BASKARAN SUBRAMANIAN | 2010-10-28 | — | — | US | disclosed |
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | BASKARAN SUBRAMANIAN | 2010-10-28 | — | — | US | disclosed |
| WO-2010091411-A1 | PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010091411-A1 | PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | ZC3HAV1, MAVS, EIF2AK2 | RORC 1748/4885TRPV1 1739/4885RBP4 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.